Table 4.
Frequency of selected adverse events in placebo and empagliflozin-treated patients, according to baseline use of a neprilysin inhibitor
| Patients not taking a neprilysin inhibitor (n = 2999) |
Patients taking a neprilysin inhibitor (n = 727) |
|||
|---|---|---|---|---|
| Placebo (n = 1476) | Empagliflozin (n = 1523) | Placebo (n = 387) | Empagliflozin (n = 340) | |
| Serious adverse events | 702 (47.6) | 631 (41.4) | 194 (50.1) | 141 (41.5) |
| Hypotension | 124 (8.4) | 132 (8.7) | 39 (10.1) | 44 (12.9) |
| Symptomatic hypotension | 75 (5.1) | 76 (5.0) | 28 (7.2) | 30 (8.8) |
| Volume depletion | 144 (9.8) | 146 (9.6) | 40 (10.3) | 51 (15.0) |
| Hyperkalaemia | 98 (6.6) | 89 (5.8) | 29 (7.5) | 20 (5.9) |
| Hypokalaemia | 24 (1.6) | 30 (2.0) | 5 (1.3) | 5 (1.5) |
| Worsening renal function | 141 (9.6) | 143 (9.4) | 51 (13.2) | 32 (9.4) |
| Acute kidney injury | 38 (2.6) | 25 (1.6) | 17 (4.4) | 10 (2.9) |
| Confirmed hypoglycaemia | 22 (1.5) | 22 (1.4) | 6 (1.6) | 5 (1.5) |
Shown are adverse events while on study medication and recorded up to 7 days following discontinuation of the study medications.